10x Genomics (TXG) Equity Average (2018 - 2026)

10x Genomics' Equity Average history runs 9 years deep, the most recent figure standing at $805.3 million for Q1 2026.

• In Q1 2026, Equity Average rose 13.66% year-over-year to $805.3 million; the TTM figure through Mar 2026 stood at $805.3 million (up 13.66% YoY), while the FY2025 annual figure was $753.2 million, up 3.81% from the prior year.
• Equity Average came in at $805.3 million for Q1 2026 at 10x Genomics, up from $790.7 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $812.1 million in Q1 2022 to a low of $708.5 million in Q1 2025.
• A 5-year average of $765.1 million and a median of $779.2 million in 2025 frame the typical range for Equity Average.
• Across the five-year window, Equity Average retreated 9.58% in 2024 and rose 13.66% in 2026, its largest moves.
• 10x Genomics' Equity Average stood at $790.8 million in 2022, then retreated by 6.02% to $743.1 million in 2023, then decreased by 3.59% to $716.5 million in 2024, then increased by 10.36% to $790.7 million in 2025, then grew by 1.85% to $805.3 million in 2026.
• According to Business Quant data, Equity Average over the past three periods registered $805.3 million, $790.7 million, and $779.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison